Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Asset Writedowns and Impairment: 2018-2025

  • Autolus Therapeutics' Asset Writedowns and Impairment was N/A to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year change of. This contributed to the annual value of $414,000 for FY2024, which is 3.50% up from last year.
  • Autolus Therapeutics' Asset Writedowns and Impairment amounted to $4.3 million in Q3 2025, which was up 477.96% from $744,000 recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Asset Writedowns and Impairment registered a high of $4.3 million during Q3 2025, and its lowest value of $744,000 during Q2 2025.
  • In the last 1 years, Autolus Therapeutics' Asset Writedowns and Impairment had a median value of $2.5 million in 2025 and averaged $2.5 million.